A phase II trial combining nivolumab and stereotactic brain radiosurgery for treatment of brain metastases in patients with NSCLC.

Philip Wong,Marie Florescu,Marc-Emile Plourde,Valerie Panet-Raymond,Michel Pavic,S. Owen,Laurence Masson-Côté,Cynthia Ménard,Bertrand Routy,Mustapha Tehfe,Normand Blais,David Roberge,Laura Masucci

A phase II trial combining nivolumab and stereotactic brain radiosurgery for treatment of brain metastases in patients with NSCLC.

2021

Philip Wong
Marie Florescu
Marc-Emile Plourde
Valerie Panet-Raymond
Michel Pavic
S. Owen
Laurence Masson-Côté
Cynthia Ménard
Bertrand Routy
Mustapha Tehfe
Normand Blais
David Roberge
Laura Masucci

2023Background: Previous studies suggested activity of anti-PD-1 in brain metastases from non-small cell lung cancer (NSCLC) and renal cell cancer (RCC). This investigator initiated phase 2 trial e...

Keywords:

cell cancer
Nivolumab
Internal medicine
Medicine
non small cell
Oncology
in patient
Radiosurgery

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations